SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial

Runbo Zhong, Huangming Hong, Min Yan, Qiming Wang, Yan Zhang, Qiongyu Lan, Yongzhong Luo, Ling Zhang, Haipeng Xu, Sanxing Guo, Wei Guo, Jie Ma, Longzhen Zhang, Lin Wu, Zhigang Liu, Wei He, Yubei Sun, Kai Chen, Jiangqiong Huang, Guang Han, Weiqi Nian, Ming Zhang, Shengxiang Ren, Rong Qiao, Xiang Li, Meijing Yu, Jin Hu, Yanhua Huang, Li Song, Wei Shi, Hua Zhong

Open source

DOI: 10.1016/s1470-2045(26)00238-x
Published: 2026-09
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00238-x,
  title = {SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial},
  author = {Runbo Zhong and Huangming Hong and Min Yan and Qiming Wang and Yan Zhang and Qiongyu Lan and Yongzhong Luo and Ling Zhang and Haipeng Xu and Sanxing Guo and Wei Guo and Jie Ma and Longzhen Zhang and Lin Wu and Zhigang Liu and Wei He and Yubei Sun and Kai Chen and Jiangqiong Huang and Guang Han and Weiqi Nian and Ming Zhang and Shengxiang Ren and Rong Qiao and Xiang Li and Meijing Yu and Jin Hu and Yanhua Huang and Li Song and Wei Shi and Hua Zhong},
  year = {2026},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(26)00238-x},
  url = {https://doi.org/10.1016/s1470-2045(26)00238-x}
}

RIS

TY  - JOUR
TI  - SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial
AU  - Runbo Zhong
AU  - Huangming Hong
AU  - Min Yan
AU  - Qiming Wang
AU  - Yan Zhang
AU  - Qiongyu Lan
AU  - Yongzhong Luo
AU  - Ling Zhang
AU  - Haipeng Xu
AU  - Sanxing Guo
AU  - Wei Guo
AU  - Jie Ma
AU  - Longzhen Zhang
AU  - Lin Wu
AU  - Zhigang Liu
AU  - Wei He
AU  - Yubei Sun
AU  - Kai Chen
AU  - Jiangqiong Huang
AU  - Guang Han
AU  - Weiqi Nian
AU  - Ming Zhang
AU  - Shengxiang Ren
AU  - Rong Qiao
AU  - Xiang Li
AU  - Meijing Yu
AU  - Jin Hu
AU  - Yanhua Huang
AU  - Li Song
AU  - Wei Shi
AU  - Hua Zhong
PY  - 2026
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(26)00238-x
UR  - https://doi.org/10.1016/s1470-2045(26)00238-x
ER  -

APA

Zhong, R., Hong, H., Yan, M., Wang, Q., Zhang, Y., Lan, Q., Luo, Y., Zhang, L., Xu, H., Guo, S., Guo, W., Ma, J., Zhang, L., Wu, L., Liu, Z., He, W., Sun, Y., Chen, K., Huang, J., Han, G., Nian, W., Zhang, M., Ren, S., Qiao, R., Li, X., Yu, M., Hu, J., Huang, Y., Song, L., Shi, W., & Zhong, H. (2026). SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00238-x

Source records

crossref · retrieved 2026-09-27T14:18:24.935Z